ICOVIR-5
AXP000050.1 · Oncolytic virus
- Platform
- adenovirus (Ad5, E2F-1 promoter-driven E1A-Delta24, RGD fiber)
- Originator
- IDIBELL / Institut Catala d'Oncologia (Ramon Alemany)
- Sponsor
- Hospital Infantil Universitario Nino Jesus
Names
| Name | Type | Source |
|---|---|---|
| ICOVIR-5 | preferred name, code | curator, ctgov |
| AloCELYVIR ambiguous | synonym | ncit |
| Celyvir ambiguous | synonym | ncit |
Virus
- Role
- Oncolytic
- Family
- Adenoviridae
- Virus
- human adenovirus 5 (NCBI Taxonomy 28285)
- Strain
- Ad5 (ICOVIR-5)
- Replication
- conditionally replicating
- Modifications
- E2F-1 promoter drives E1A-Delta24; RGD-4C fiber; Sp1 insulator
- Route
- intravenous
- Carrier
- bone marrow mesenchymal stromal cells (Celyvir, AloCELYVIR)
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (2)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT01864759 | Phase I Endovenous Administration of Oncolytic Adenovirus ICOVIR-5 in Patients With Advanced or Metastatic Melanoma | Completed | Phase 1 | 2013-01-11 | 2016-12-20 | 14 | Locally Advanced or Metastatic Melanoma |
| NCT01844661 | Safety and Efficacy of Repeated Infusion of CELYVIR in Children and Adults With Metastatic and Refractory Tumors. | Completed | Phase 1/2 | 2013-01 | 2014-12 | 20 | Children; Metastases; Solid Tumors |
Unconfirmed matches (2)
Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions | Matched by |
|---|---|---|---|---|---|---|---|---|
| NCT05047276 | Phase I/II Study of AloCelyvir in Patients With Metastatic Uveal Melanoma | Unknown | Phase 1/2 | 2021-10-01 | 2023-06-30 | 16 | Uveal Melanoma, Metastatic | intervention named: AloCELYVIR |
| NCT04758533 | Clinical Trial to Assess the Safety and Efficacy of AloCELYVIR With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) in Combination With Radiotherapy or Medulloblastoma in Monotherapy | Active not recruiting | Phase 1/2 | 2021-04-19 | 2026-04 | 13 | Diffuse Intrinsic Pontine Glioma; Medulloblastoma, Childhood, Recurrent | intervention named: AloCELYVIR |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 33737338 | Combination immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in osteosarcoma. | Journal for immunotherapy of cancer | 2021 | cited by trial NCT01844661 |
| PMID 32028001 | Longitudinal Monitoring of Gd-DTPA Following Convection Enhanced Delivery in the Brainstem. | World neurosurgery | 2020 | name in abstract: ICOVIR-5 |
| PMID 32053771 | First-in-Human, First-in-Child Trial of Autologous MSCs Carrying the Oncolytic Virus Icovir-5 in Patients with Advanced Tumors. | Molecular therapy : the journal of the American Society of Gene Therapy | 2020 | cited by trial NCT01844661 |
| PMID 30234393 | A Phase 1 Trial of Oncolytic Adenovirus ICOVIR-5 Administered Intravenously to Cutaneous and Uveal Melanoma Patients. | Human gene therapy | 2019 | name in title: ICOVIR-5 |
| PMID 24327128 | Superselective intracerebral catheterization for administration of oncolytic virotherapy in a case of diffuse intrinsic pontine glioma. | Journal of pediatric hematology/oncology | 2014 | name in abstract: ICOVIR-5 |
| PMID 20168350 | Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study. | Cancer gene therapy | 2010 | name in abstract: ICOVIR-5 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41705010 | A Decade of Oncolytic Virotherapy in Pediatric Cancers: A Systematic Review of Safety, Immune Awakening, and Emerging Efficacy. | Cureus | 2026 | name in abstract: ICOVIR-5 |
| PMID 41741902 | Clinical and translational progress in oncolytic virotherapy for pediatric CNS tumors. | Journal of neuro-oncology | 2026 | name in abstract: ICOVIR-5 |
| PMID 39290319 | Deletion of the RGD motif from the penton base in oncolytic adenoviruses enhances antitumor efficacy of combined CAR T cell therapy. | Molecular therapy. Oncology | 2024 | name in abstract: ICOVIR-5 |
| PMID 32457488 | AKT and JUN are differentially activated in mesenchymal stem cells after infection with human and canine oncolytic adenoviruses. | Cancer gene therapy | 2021 | name in abstract: ICOVIR-5 |
| PMID 32354143 | Genetic and Immune Changes Associated with Disease Progression under the Pressure of Oncolytic Therapy in A Neuroblastoma Outlier Patient. | Cancers | 2020 | name in abstract: ICOVIR-5 |
| PMID 30322950 | Enhanced Antitumor Efficacy of Oncolytic Adenovirus-loaded Menstrual Blood-derived Mesenchymal Stem Cells in Combination with Peripheral Blood Mononuclear Cells. | Molecular cancer therapeutics | 2019 | name in abstract: ICOVIR-5 |
| PMID 30066102 | Antitumor virotherapy using syngeneic or allogeneic mesenchymal stem cell carriers induces systemic immune response and intratumoral leukocyte infiltration in mice. | Cancer immunology, immunotherapy : CII | 2018 | name in abstract: ICOVIR-5 |
| PMID 28525366 | Mesenchymal stem cell carriers enhance antitumor efficacy of oncolytic adenoviruses in an immunocompetent mouse model. | Oncotarget | 2017 | name in abstract: ICOVIR-5 |
| PMID 20179683 | Verapamil enhances the antitumoral efficacy of oncolytic adenoviruses. | Molecular therapy : the journal of the American Society of Gene Therapy | 2010 | name in abstract: ICOVIR-5 |
| PMID 21381281 | [The use of oncolytic adenovirus for the treatment of cancer]. | Methods and findings in experimental and clinical pharmacology | 2010 | name in abstract: ICOVIR-5 |
| PMID 17557108 | Combination of the oncolytic adenovirus ICOVIR-5 with chemotherapy provides enhanced anti-glioma effect in vivo. | Cancer gene therapy | 2007 | name in title: ICOVIR-5 |
| PMID 17579575 | Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathway. | Molecular therapy : the journal of the American Society of Gene Therapy | 2007 | name in title: ICOVIR-5 |
| PMID 17804740 | ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo. | Cancer research | 2007 | name in title: ICOVIR-5 |
Unconfirmed matches (2)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 42458857 | Celyvir: Oncolytic Virotherapy with Mesenchymal Stromal Cells. From Concept to Clinical Translation. | Human gene therapy | 2026 | name in title: Celyvir |
| PMID 39946782 | Exploring neuroblastoma's cellular microenvironment: A novel approach using cellular automata to model Celyvir treatment. | Computers in biology and medicine | 2025 | name in title: Celyvir |
Notes
Given both naked (phase I melanoma, NCT01864759) and carried in bone-marrow mesenchymal stromal cells as Celyvir (autologous, NCT01844661) and AloCELYVIR (allogeneic, NCT04758533). Treated here as one program with a carrier, not three; a curator may prefer to split the cell products out.
How to cite
ICOVIR-5 (AXP000050.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000050.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.